Heike Liewen

Heike Liewen

Auto-generated profile, based on publicly available information

Heike Liewen

Department of Oncology, University Hospital Zurich, Zurich, Switzerland

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2005 in Experimental Cell Research
Verified
Journal Article
Closed access
HLHeike Liewen
Heike Liewen
IMIvo Meinhold-Heerlein
Ivo Meinhold-Heerlein
VOVasco Oliveira
Vasco Oliveira
RSRobert Schwarzenbacher
Robert Schwarzenbacher
GLGuorong Luo
Guorong Luo
FSFrank Stenner-Liewen
Frank Stenner-Liewen

27 April 2009 in Hepatology
Verified
Journal Article
Open access
PDF file
MRMarc-Oliver Riener
Marc-Oliver Riener
FSFrank Stenner
Frank Stenner
HLHeike Liewen
Heike Liewen
CSChristopher Soll
Christopher Soll
SBStefan Breitenstein
Stefan Breitenstein
GKGlen Kristiansen
Glen Kristiansen
Hepatocellular carcinomas (HCCs) and bile duct carcinomas (BDCs) have a poor prognosis. Therefore, surveillance strategies including sensitive and specific serum markers for early detection are needed. Recently, Golgi Phosphoprotein 2 (GOLPH2) has been proposed as a serum marker for HCC, but GOLPH2 expression data in liver tissues was not available. Using tissue microarrays and immunohistochemistry, we semiquantitatively analyzed GOLPH2 protein expression in patients with HCC (n = 170), benign liver tumors (n = 22), BDC (n = 114) and normal liver tissue (n = 105). A newly designed sandwich enzyme-linked immunoassay (ELISA) was used to analyze GOLPH2 levels in the sera of patients with HCC (n = 62), hepatitis C virus (HCV) (n = 29), BDC (n = 10), and healthy control persons (n = 12). By immunohistochemistry 121/170 (71%) of HCC showed strong GOLPH2 expression, which was significantly associated with a higher tumor grade (P = 0.01). A total of 97/114 (85%) BDCs showed a strong GOLPH2 expression which proved to be an independent prognostic factor for overall survival (P < 0.05). Serum levels of GOLPH2 measured by ELISA were significantly elevated in patients with HCC with underlying HCV infection (median 18 mg/L, P < 0.05) and patients with BDC (median = 14.5 mg/L, P < 0.01) in comparison to healthy controls (median 4 mg/L). Conclusion: GOLPH2 protein is highly expressed in tissues of HCC and BDC. GOLPH2 protein levels are detectable and quantifiable in sera by ELISA. In patients with hepatitis C, serial ELISA measurements in the course of the disease appear to be a promising complementary serum marker in the surveillance of HCC. GOLPH2 should be further evaluated as a serum tumor marker in BDC on a larger scale. (Hepatology 2009.)

1 March 2002 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
FSFrank Stenner-Liewen
Frank Stenner-Liewen
HLHeike Liewen
Heike Liewen
Juan Manuel ZapataJuan Manuel Zapata
Juan Manuel Zapata
KPKrzysztof Pawłowski
Krzysztof Pawłowski
AGAdam Godzik
Adam Godzik
JRJohn C. Reed
John C. Reed
We report here the identification of a bacterial protein capable of interacting with mammalian death receptors in vitro and in vivo. The protein is encoded in the genome of Chlamydia trachomatis and has homologues in otherChlamydia species. This protein, which we refer to as “ C hlamydia protein associating with death domains” (CADD), induces apoptosis in a variety of mammalian cell lines when expressed by transient gene transfection. Apoptosis induction can be blocked by Caspase inhibitors, indicating that CADD triggers cell death by engaging the host apoptotic machinery. CADD interacts with death domains of tumor necrosis factor (TNF) family receptors TNFR1, Fas, DR4, and DR5 but not with the respective downstream adaptors. In infected epithelial cells, CADD is expressed late in the infectious cycle of C. trachomatisand co-localizes with Fas in the proximity of the inclusion body. The results suggest a role for CADD modulating the apoptosis pathways of cells infected, revealing a new mechanism of host-pathogen interaction.

1 July 2004 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
RSRobert Schwarzenbacher
Robert Schwarzenbacher
FSFrank Stenner-Liewen
Frank Stenner-Liewen
HLHeike Liewen
Heike Liewen
HRHoward Robinson
Howard Robinson
HYHua Yuan
Hua Yuan
RLRobert C. Liddington
Robert C. Liddington
The Chlamydia protein CADD (Chlamydia protein associating with death domains) has been implicated in the modulation of host cell apoptosis via binding to the death domains of tumor necrosis factor family receptors. Transfection of CADD into mammalian cells induces apoptosis. Here we present the CADD crystal structure, which reveals a dimer of seven-helix bundles. Each bundle contains a di-iron center adjacent to an internal cavity, forming an active site similar to that of methane mono-oxygenase hydrolase. We further show that CADD mutants lacking critical metal-coordinating residues are substantially less effective in inducing apoptosis but retain their ability to bind to death domains. We conclude that CADD is a novel redox protein toxin unique to Chlamydia species and propose that both its redox activity and death domain binding ability are required for its biological activity.

1 March 2016 in European Journal of Cancer
Verified
Journal Article
Closed access
AMAlexander Meisel
Alexander Meisel
SFStefanie von Felten
Stefanie von Felten
DVDeborah Vogt
Deborah Vogt
HLHeike Liewen
Heike Liewen
RWRonald de Wit
Ronald de Wit
FSFrank Stenner-Liewen
Frank Stenner-Liewen

1 April 2001 in The American Journal of Pathology
Verified
Journal Article
Closed access
IMIvo Meinhold-Heerlein
Ivo Meinhold-Heerlein
FSFrank Stenner-Liewen
Frank Stenner-Liewen
HLHeike Liewen
Heike Liewen
SKShinichi Kitada
Shinichi Kitada
MKMaryla Krajewska
Maryla Krajewska
JRJohn C. Reed
John C. Reed